Blockchain Registration Transaction Record

Oncotelic's Nose-to-Brain Platform Tackles Alzheimer's and Biodefense

Oncotelic Therapeutics featured in BioMedWire editorial for its intranasal nose-to-brain drug delivery platform targeting Alzheimer's and biodefense. Learn how OTLC's technology bypasses the blood-brain barrier.

Oncotelic's Nose-to-Brain Platform Tackles Alzheimer's and Biodefense

This news matters because it highlights a breakthrough in drug delivery that could transform treatment for Alzheimer's disease and other CNS disorders. Oncotelic's intranasal platform offers a non-invasive method to bypass the blood-brain barrier, potentially improving efficacy and reducing side effects for millions of patients. For investors, it signals a growing focus on CNS therapeutics and the company's innovative edge in a high-demand market.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x634050378a126e4a70e565a25f64a41a31bb344c3056a2bd1de3a133c1fe5c2a
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintninotWkw-191b35cbf07d33072cc9c2d894a14d17